**Categories/Vocabulary**

|  |  |  |
| --- | --- | --- |
| Alliance id | Main heading | Subheading |
| 3 | Accreditation | Accreditation of clinical research sites |
| 5 | Accreditation | *In Silico* DMPK expert |
| 5 | Co-crystallization | Industry framework for co-crystallization |
| 1 | Collaboration | Pre-competitive collaboration |
| 1 | Collaboration | Collaborate on open projects |
| 1 | Collaboration | Pool resources |
| 3 | Collaboration | Collaborate on building integrated, comprehensive global system for clinical research |
| 3 | Collaboration | Bring together all of the stakeholders representing all of the “parts” of the clinical research endeavor |
| 5 | Collaboration | Encouraging external collaborations |
| 5 | Collaboration | Advancing relationships with professional organizations, other consortia, and academic and government research institutes |
| 5 | Collaboration | Innovation through precompetitive collaboration |
| 5 | Collaboration | 3Rs European liaison |
| 5 | Collaboration | 3Rs US NGO Outreach |
| 5 | Collaboration | 3Rs Benchmarking (cross-disciplinary) |
| 5 | Collaboration | Imaging MS discussion group |
| 5 | Collaboration | Joint DMLG/CPLG transporter working group |
| 5 | Collaboration | PK/PD discussion group |
| 5 | Collaboration | Preclinical suicidality |
| 5 | Collaboration | Therapeutic Proteins drug-drug interactions |
| 5 | Collaboration | Novel excipients |
| 1 | Communication and dissemination | Openly publish resources |
| 5 | Communication and dissemination | Organizes conferences |
| 5 | Communication and dissemination | Runs webinars |
| 1 | Communication and dissemination | Runs webinars |
| 5 | Communication and dissemination | Provide forum for exchange of ideas |
| 5 | Communication and dissemination | Dissemination of technical positions |
| 5 | Communication and dissemination | Organizes meetings |
| 5 | Communication and dissemination | Two-way communication with global regulatory authorities |
| 5 | Communication and Dissemination | 3Rs European liaison |
| 5 | Communication and Dissemination | 3Rs US NGO Outreach |
| 5 | Communication and Dissemination | Imaging MS discussion group |
| 5 | Communication and Dissemination | PK/PD discussion group |
| 5 | Communication and Dissemination | Preclinical suicidality |
| 5 | Communication and Dissemination | Quality risk management |
| 5 | Communication and dissemination | Therapeutic Proteins DDI |
| 5 | Communication and Dissemination | Drug Product Performance Characterization |
| 5 | Communication and dissemination | Extemporaneous Formulations |
| 5 | Communication and dissemination | Novel excipients |
| 5 | Communication and dissemination | *In Silico* DMPK expert |
| 5 | Comparison | 3Rs Benchmarking (cross-disciplinary) |
| 5 | Comparison | Analytical method comparability |
| 3 | Culture and ethics | Excellence in clinical research |
| 3 | Culture and ethics | Implementing culture of sharing QA data |
| 3 | Culture and ethics | Ethics in clinical development |
| 3 | Culture and ethics | Capacity building in developing countries |
| 5 | Culture and ethics | 3Rs European liaison |
| 5 | Culture and ethics | 3Rs US NGO Outreach |
| 5 | Culture and ethics | 3Rs Benchmarking (cross-disciplinary) |
| 5 | Culture and ethics | Change management in development |
| 5 | Culture and ethics | *In Silico* DMPK expert |
| 5 | Drug metabolism | Joint DMLG/CPLG transporter working group |
| 5 | Drug metabolism | Assessment of *in vivo* Human Metabolism (biology) |
| 5 | Drug metabolism | Radiolabeled Materials |
| 5 | Drug metabolism | Drug-Drug Interaction Victim Working Group |
| 5 | Drug metabolism | Antibody Drug Conjugates (ADME) |
| 5 | Drug metabolism | CYP activity |
| 5 | Drug-drug Interaction | Therapeutic Proteins DDI |
| 5 | Drug-drug Interaction | Drug-Drug Interaction Victim Working Group |
| 5 | Drug-drug interactions | Joint DMLG/CPLG transporter working group |
| 5 | Formulation | Pediatric formulations |
| 5 | Formulation | Drug Product Performance Characterization |
| 5 | Formulation | Extemporaneous Formulations (CMC) |
| 5 | Formulation | Novel excipients |
| 5 | GMP | GMPs in early development |
| 5 | Imaging | Imaging MS discussion group |
| 5 | Microsampling analysis | Microsampling (drug metabolism) |
| 5 | Pharmaceutical product quality | Regulations for pharmaceutical and biotechnology products |
| 5 | Pharmaceutical product quality | Detection of counterfeit products |
| 5 | Pharmaceutical product quality | Drug product differentiation |
| 5 | Pharmaceutical product quality | Implementation of ICH Q10 |
| 5 | Pharmaceutical product quality | Impurity control |
| 5 | Pharmaceutical product quality | Impurity control |
| 5 | Pharmaceutical product quality | Quality by Design (QbD) |
| 5 | Pharmaceutical product quality | Quality risk management |
| 5 | Pharmaceutical product quality | Drug Product Performance Characterization |
| 5 | Pharmaceutical product quality | Process Analytical Technology PAT)/Real-Time Release(RTR) |
| 2 | Platform | Deliver clinical data warehouse |
| 2 | Platform | Deliver standardized data system |
| 2 | Platform | Deliver common IT methodology |
| 2 | Platform | Deliver hosted solution |
| 3 | Platform | Collaborate on building integrated, comprehensive global system for clinical research |
| 6 | Platform | Provides a cloud platform |
| 2 | Platform | Provides a cloud platform |
| 2 | Platform | Digitally enable the R&D function |
| 5 | Platform | Non-clinical to clinical translation (preclinical safety) |
| 1 | Proof of concept | Develop technology pilots |
| 4 | Proof of concept | Delivers proof of concept applications |
| 1 | Proof of concept | Delivers proof of concept applications |
| 5 | QT prolongation | QTc prolongation |
| 5 | QT prolongation | QT (TQT) |
| 5 | Regulatory | Two-way communication with global regulatory authorities |
| 5 | Regulatory | Regulations for pharmaceutical and biotechnology products |
| 5 | Regulatory | Joint DMLG/CPLG transporter working group |
| 5 | Regulatory | Preclinical suicidality |
| 5 | Regulatory | Physiologically based pharmacokinetics (PBPK) Modeling White Paper (biology) |
| 5 | Regulatory | QT (TQT) |
| 5 | Regulatory | Antibody Drug Conjugates (ADME) |
| 1 | Share data | Share data essential to innovation |
| 5 | Share data | Creating cross-functional datasets |
| 6 | Share data | Shares data |
| 6 | Share data | Provides datasets |
| 3 | Share data | Implementing culture of sharing QA data |
| 5 | Share data | Single location for metadata repository |
| 1 | Standards | Develop best practices |
| 1 | Standards | Be a source of impartial opinion |
| 1 | Standards | Be a community of experts |
| 2 | Standards | Deliver common IT methodology |
| 2 | Standards | Employ integrated information technologies and interoperable standards |
| 3 | Standards | Collaborate on building integrated, comprehensive global system for clinical research |
| 4 | Standards | Development of metadata dictionaries |
| 4 | Standards | Development of data standards |
| 4 | Standards | Development of class libraries |
| 5 | Standards | Advances standards |
| 5 | Standards | Establishing best practices |
| 5 | Standards | Build consensus with regulators |
| 5 | Standards | Collaboration across member companies to create scientific positions |
| 2 | Standards | Digitally enable the R&D function |
| 1 | Standards | Representation of biomolecules |
| 1 | Standards | Controlled substance compliance |
| 1 | Standards | Best practices for ontology management |
| 3 | Standards | Accreditation of clinical research sites |
| 3 | Standards | Standards for compliance data in clinical research |
| 3 | Standards | Safety engineering techniques in clinical research |
| 4 | Standards | Document standards (e.g., AnIML) |
| 4 | Standards | Single location for metadata repository |
| 5 | Standards | 3Rs Benchmarking (cross-disciplinary) |
| 5 | Standards | Analytical method comparability |
| 5 | Standards | Detection of counterfeit products |
| 5 | Standards | Drug product differentiation |
| 5 | Standards | GMPs in early development |
| 5 | Standards | Implementation of ICH Q10 |
| 5 | Standards | Industry framework for co-crystallization |
| 5 | Standards | Microsampling (drug metabolism) |
| 5 | Standards | Quality by Design (QbD) |
| 5 | Standards | Quality risk management |
| 5 | Standards | Quality standards in non–regulatory labs |
| 5 | Standards | Physiologically based pharmacokinetics (PBPK) Modeling White Paper (biology) |
| 5 | Standards | QT (TQT) |
| 5 | Standards | Radiolabeled Materials |
| 5 | Standards | Drug-Drug Interaction Victim Working Group |
| 5 | Standards | Antibody Drug Conjugates (ADME) |
| 5 | Toxicity models | 3Rs European liaison |
| 5 | Toxicity models | 3Rs US NGO Outreach |
|  | Toxicity models | 3Rs Benchmarking (cross-disciplinary) |
| 5 | Toxicity models | *In vitro* repro/developmental assay predictivity |
| 5 | Toxicity models | Non-clinical to clinical translation (preclinical safety) |
| 5 | X Unknown | Bioanalysis expert |
| 5 | X Unknown | Developability assessment |
| 5 | X Unknown | Process validation exploratory |

Maybe more than one organization involves “regulatory”?

I have “precompetitive” as a type of organization. Maybe it should be in here instead?

Note that a platform needs standards. I have not automatically added “standards” for every platform since some platforms may use standards set by other bodies